Going viral with cancer immunotherapy (original) (raw)

• Glenney, J. R. Jr., Zokas, L. & Kamps, M. P. Monoclonal antibodies to phosphotyrosine. J. Immunol. Methods 109, 277–285 (1988).
  Article CAS PubMed Google Scholar
• Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252–264 (2012).
  Article CAS Google Scholar
• Kreiter, S., Castle, J. C., Tureci, O. & Sahin, U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1, 768–769 (2012).
  Article PubMed PubMed Central Google Scholar
• Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nature Biotech. 30, 658–670 (2012).
  Article CAS Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  CAS PubMed Google Scholar
• Kelly, E. & Russell, S. J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651–659 (2007).
  Article CAS PubMed Google Scholar
• Parato, K. A. et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 4, 749–758 (2011).
  Google Scholar
• Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263–275 (2003).
  Article CAS PubMed Google Scholar
• Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99–102 (2011).
  Article CAS PubMed Google Scholar
• Liu, T. C., Hwang, T., Park, B. H., Bell, J. & Kirn, D. H. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol. Ther. 16, 1637–1642 (2008).
  Article CAS PubMed Google Scholar
• Breitbach, C. J. et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73, 1265–1275 (2013).
  Article CAS PubMed Google Scholar
• Breitbach, C. J. et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686–1693 (2007).
  Article CAS PubMed Google Scholar
• Breitbach, C. J. et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886–894 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, T. C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Clin. Pract. Oncol. 4, 101–117 (2007).
  Article CAS Google Scholar
• Vacchelli, E. et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2, e24612 (2013).
  Article PubMed PubMed Central Google Scholar
• Miest, T. S. & Cattaneo, R. New viruses for cancer therapy: meeting clinical needs. Nature Rev. Microbiol. 12, 23–34 (2013).
  Article CAS Google Scholar
• Atherton, M. J. & Lichty, B. D. Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy 5, 1191–1206 (2013).
  Article CAS PubMed Google Scholar
• Kaufman, H. L. & Bines, S. D. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 6, 941–949 (2010).
  Article CAS PubMed Google Scholar
• Garber, K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98, 298–300 (2006).
  Article PubMed Google Scholar
• Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763–5771 (2009).
  Article CAS PubMed Google Scholar
• Nemunaitis, J. et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746–759 (2001).
  Article CAS PubMed Google Scholar
• Park, B. H. et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533–542 (2008).
  Article CAS PubMed Google Scholar
• Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Med. 19, 329–336 (2013).
  Article CAS PubMed Google Scholar
• Ingemar Andtbacka, R. H. et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C & IV melanoma. J. Clin. Oncol. 31, abstract LBA9008 (2013).
• Harrington, K. J. et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005–4015 (2010).
  Article CAS PubMed Google Scholar
• Harrington, K. J. et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin. Cancer Res. 16, 3067–3077 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Heo, J. et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther. 19, 1170–1179 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Cerullo, V. et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737–1746 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 363, 411–422 (2010).
  Article CAS PubMed Google Scholar
• Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).
  Article CAS PubMed Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 363, 711–723 (2010).
  Article CAS PubMed Google Scholar
• Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Dudley, M. E. & Rosenberg, S. A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Rev. Cancer 3, 666–675 (2003).
  Article CAS Google Scholar
• Kershaw, M. H., Westwood, J. A. & Darcy, P. K. Gene-engineered T cells for cancer therapy. Nature Rev. Cancer 13, 525–541 (2013).
  Article CAS Google Scholar
• Adair, R. A. et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci. Transl. Med. 4, 138ra77 (2012).
  PubMed PubMed Central Google Scholar
• Kottke, T. et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther. 16, 1217–1226 (2008).
  Article CAS PubMed Google Scholar
• Diaz, R. M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67, 2840–2848 (2007).
  Article CAS PubMed Google Scholar
• Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292–303 (2003).
  Article CAS PubMed Google Scholar
• Moehler, M. H. et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 16, 996–1005 (2005).
  Article CAS PubMed Google Scholar
• Mastrangelo, M. J. et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409–422 (1999).
  Article CAS PubMed Google Scholar
• Hwang, T. H. et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19, 1913–1922 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, M. K. et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci. Transl. Med. 5, 185ra63 (2013).
  Article CAS PubMed Google Scholar
• Sukkurwala, A. Q. et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ. 21, 59–68 (2014).
  Article CAS PubMed Google Scholar
• Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nature Med. 15, 1170–1178 (2009).
  Article CAS PubMed Google Scholar
• Zelenay, S. et al. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J. Clin. Invest. 122, 1615–1627 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, B. H. et al. Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS ONE 7, e35812 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, B., Sikorski, R., Kirn, D. H. & Thorne, S. H. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 18, 164–172 (2011).
  Article CAS PubMed Google Scholar
• Miyamoto, S. et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 72, 2609–2621 (2012).
  Article CAS PubMed Google Scholar
• Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Galivo, F. et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum. Gene Ther. 21, 439–450 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Schirrmacher, V., Griesbach, A. & Ahlert, T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int. J. Oncol. 18, 945–952 (2001).
  CAS PubMed Google Scholar
• Diallo, J. S. et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 18, 1123–1129 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Nguyen, T. L. et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl Acad. Sci. USA 105, 14981–14986 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Jha, B. K., Dong, B., Nguyen, C. T., Polyakova, I. & Silverman, R. H. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol. Ther. 21, 1749–1757 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bose, A. et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int. J. Cancer 129, 2158–2170 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Beug, S. T. et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature Biotech. 32, 182–190 (2014).
  Article CAS Google Scholar
• Hu, J. C. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737–6747 (2006).
  Article CAS PubMed Google Scholar
• Curran, M. A. & Allison, J. P. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 69, 7747–7755 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Epardaud, M. et al. Interleukin-15/interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68, 2972–2983 (2008).
  Article CAS PubMed Google Scholar
• Liu, R. B. et al. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc. Natl Acad. Sci. USA 110, 8158–8163 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Onu, A., Pohl, T., Krause, H. & Bulfone-Paus, S. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J. Immunol. 158, 255–262 (1997).
  CAS PubMed Google Scholar
• Yu, F. et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol. Ther. 22, 102–111 (2014).
  Article CAS PubMed Google Scholar
• Amato, R. J. et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin. Cancer Res. 14, 7504–7510 (2008).
  Article CAS PubMed Google Scholar
• Harrop, R. et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin. Cancer Res. 12, 3416–3424 (2006).
  Article CAS PubMed Google Scholar
• Horig, H. et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49, 504–514 (2000).
  Article CAS PubMed Google Scholar
• Jager, E. et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103, 14453–14458 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kaufman, H. L. et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin. Cancer Res. 14, 4843–4849 (2008).
  Article CAS PubMed Google Scholar
• Madan, R. A. et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13, 501–508 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Morse, M. A. et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 62, 1293–1301 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Odunsi, K. et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl Acad. Sci. USA 109, 5797–5802 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Harrop, R., John, J. & Carroll, M. W. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev. 58, 931–947 (2006).
  Article CAS PubMed Google Scholar
• Elzey, B. D., Siemens, D. R., Ratliff, T. L. & Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842–849 (2001).
  Article CAS PubMed Google Scholar
• Hodge, J. W., McLaughlin, J. P., Kantor, J. A. & Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15, 759–768 (1997).
  Article CAS PubMed Google Scholar
• Hodge, J. W. et al. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63, 7942–7949 (2003).
  CAS PubMed Google Scholar
• Irvine, K. R. et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl Cancer Inst. 89, 1595–1601 (1997).
  Article CAS PubMed Google Scholar
• Marshall, J. L. et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964–3973 (2000).
  Article CAS PubMed Google Scholar
• Naslund, T. I. et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178, 6761–6769 (2007).
  Article PubMed Google Scholar
• Bridle, B. W. et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18, 1430–1439 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Vigil, A., Martinez, O., Chua, M. A. & Garcia-Sastre, A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16, 1883–1890 (2008).
  Article CAS PubMed Google Scholar
• Pol, J. G. et al. Maraba virus as a potent oncolytic vaccine vector. Mol. Ther. 22, 420–429 (2014).
  Article CAS PubMed Google Scholar
• Loi, S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2, e24720 (2013).
  Article PubMed PubMed Central Google Scholar
• Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Puzanov, I. et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin. Oncol. 32 (suppl; abstr 9029^) (2014).
  Article Google Scholar
• Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Med. 14, 1264–1270 (2008).
  Article CAS PubMed Google Scholar
• Martins, I. et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30, 1147–1158 (2011).
  Article CAS PubMed Google Scholar
• Galluzzi, L. & Kroemer, G. Autophagy mediates the metabolic benefits of endurance training. Circ. Res. 110, 1276–1278 (2012).
  Article CAS PubMed Google Scholar
• Kaczmarek, A., Vandenabeele, P. & Krysko, D. V. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209–223 (2013).
  Article CAS PubMed Google Scholar
• Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nature Rev. Cancer 12, 860–875 (2012).
  Article CAS Google Scholar
• Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718–730 (2010).
  Article PubMed Google Scholar
• Kim, J. H. et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361–370 (2006).
  Article CAS PubMed Google Scholar
• Lee, J. H. et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 17, 73–79 (2010).
  Article CAS PubMed Google Scholar
• Cerullo, V. et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 70, 4297–4309 (2010).
  Article CAS PubMed Google Scholar
• Chang, J. et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol. Ther. 8, 676–682 (2009).
  Article CAS PubMed Google Scholar
• Robinson, M. et al. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J. Virol. 83, 3450–3462 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Vigil, A. et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67, 8285–8292 (2007).
  Article CAS PubMed Google Scholar
• Grote, D., Cattaneo, R. & Fielding, A. K. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 63, 6463–6468 (2003).
  CAS PubMed Google Scholar
• Bergman, I., Griffin, J. A., Gao, Y. & Whitaker-Dowling, P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int. J. Cancer 121, 425–430 (2007).
  Article CAS PubMed Google Scholar
• Bernt, K. M., Ni, S., Tieu, A. T. & Lieber, A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res. 65, 4343–4352 (2005).
  Article CAS PubMed Google Scholar
• Ramakrishna, E. et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res. 69, 1448–1458 (2009).
  Article CAS PubMed Google Scholar
• Leveille, S., Goulet, M. L., Lichty, B. D. & Hiscott, J. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J. Virol. 85, 12160–12169 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lapteva, N. et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J. Immunother. 32, 145–156 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Li, J. et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol. Ther. 19, 650–657 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Carew, J. F. et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol. Ther. 4, 250–256 (2001).
  Article CAS PubMed Google Scholar
• Zhao, H., Janke, M., Fournier, P. & Schirrmacher, V. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res. 136, 75–80 (2008).
  Article CAS PubMed Google Scholar
• Post, D. E. et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 67, 6872–6881 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Terada, K., Wakimoto, H., Tyminski, E., Chiocca, E. A. & Saeki, Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 13, 705–714 (2006).
  Article CAS PubMed Google Scholar
• Choi, I. K. et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther. 18, 898–909 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, Y. S. et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin. Cancer Res. 12, 5859–5868 (2006).
  Article CAS PubMed Google Scholar
• Derubertis, B. G. et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther. 14, 590–597 (2007).
  Article CAS PubMed Google Scholar
• Varghese, S. et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13, 253–265 (2006).
  Article CAS PubMed Google Scholar
• Shin, E. J. et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 117, 210–214 (2007).
  Article CAS PubMed Google Scholar
• Gaston, D. C. et al. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS ONE 8, e81768 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Stephenson, K. B., Barra, N. G., Davies, E., Ashkar, A. A. & Lichty, B. D. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 19, 238–246 (2012).
  Article CAS PubMed Google Scholar
• van Rikxoort, M. et al. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS ONE 7, e36506 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R. L. & Todo, T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 65, 10663–10668 (2005).
  Article CAS PubMed Google Scholar
• Ino, Y., Saeki, Y., Fukuhara, H. & Todo, T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 12, 643–652 (2006).
  Article CAS PubMed Google Scholar
• Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J. & Thorne, S. H. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Li, H., Peng, K. W., Dingli, D., Kratzke, R. A. & Russell, S. J. Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17, 550–558 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shashkova, E. V., Spencer, J. F., Wold, W. S. & Doronin, K. Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15, 598–607 (2007).
  Article CAS PubMed Google Scholar
• Shashkova, E. V., Kuppuswamy, M. N., Wold, W. S. & Doronin, K. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61–72 (2008).
  Article CAS PubMed Google Scholar
• Willmon, C. L. et al. Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 69, 7713–7720 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Su, C. et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 13, 918–927 (2006).
  Article CAS PubMed Google Scholar
• Choi, K. J. et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther. 13, 1010–1020 (2006).
  Article CAS PubMed Google Scholar
• Todo, T., Martuza, R. L., Dallman, M. J. & Rabkin, S. D. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61, 153–161 (2001).
  CAS PubMed Google Scholar
• Huang, J. H. et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol. Ther. 18, 264–274 (2010).
  Article CAS PubMed Google Scholar
• Kim, H. S., Kim-Schulze, S., Kim, D. W. & Kaufman, H. L. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res. 69, 8516–8525 (2009).
  Article CAS PubMed Google Scholar
• Li, J. L. et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 16, 376–382 (2009).
  Article CAS PubMed Google Scholar
• Yoo, J. Y. et al. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus. J. Gene Med. 12, 586–595 (2010).
  Article CAS PubMed Google Scholar
• Hu, Z. B. et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther. 15, 173–182 (2008).
  Article CAS PubMed Google Scholar